← Back to news
FDA

FDA Approves Lilly's Foundayo — the First GLP-1 Pill You Can Take Any Time Without Food Restrictions

#FDA#orforglipron#Foundayo#GLP-1#Eli Lilly#obesity#oral drug#weight loss

The U.S. Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026, making it the second oral GLP-1 receptor agonist to reach the U.S. market for obesity — and the first that patients can take at any time of day without worrying about food or water. Eli Lilly developed the drug through a licensing agreement with Japan's Chugai Pharmaceutical, and it represents a fundamentally different approach to oral GLP-1 therapy.

Why It Matters

Orforglipron, a small-molecule (non-peptide) GLP-1 receptor agonist, sidesteps one of the biggest inconveniences of existing oral semaglutide: the requirement to take the pill on an empty stomach with only a small sip of water, then wait 30 minutes before eating. Foundayo eliminates all of those restrictions.

In Phase 3 trials, patients taking the highest dose of orforglipron lost an average of 7.9% to 9.4% of their body weight over 36 weeks — meaningful, though less than the 15–20% weight loss seen with injectable tirzepatide (Mounjaro/Zepbound) or injectable semaglutide (Wegovy). The trade-off is convenience: a once-daily pill with no injection anxiety, no refrigeration, and no timing constraints.

The Oral GLP-1 Race

Foundayo's approval comes roughly three months after Novo Nordisk launched its oral semaglutide tablets for obesity in January 2026. The two drugs now compete head-to-head in a market that analysts project could exceed $100 billion annually by 2030.

Key differences between the two oral options:

  • Foundayo (orforglipron): Small molecule, no food/water restrictions, once daily, lower weight loss magnitude
  • Oral Wegovy (semaglutide): Peptide-based, must be taken on empty stomach with water restrictions, higher weight loss in trials

Behind them, Structure Therapeutics is advancing aleniglipron, another oral small-molecule GLP-1 agonist that showed 16.3% placebo-adjusted weight loss in Phase 2 and is headed to Phase 3 in the second half of 2026.

What This Means for Patients

For the estimated 100 million American adults living with obesity, Foundayo adds a genuinely new option. Many patients who were reluctant to start injectable therapy — or who struggled with the strict dosing requirements of oral semaglutide — now have an alternative that fits more easily into daily life.

Pricing has not yet been finalized, but analysts expect Foundayo to launch at a list price comparable to other GLP-1 therapies, in the range of $900–$1,200 per month before insurance. The real question will be whether insurers and pharmacy benefit managers cover it as broadly as they do injectable options.

The Bigger Picture

The approval also signals a shift in the GLP-1 landscape from peptide-based biologics toward small-molecule oral drugs. While injectable semaglutide and tirzepatide remain the gold standard for maximum weight loss, the convenience factor of oral options like Foundayo could dramatically expand the total number of patients who start — and stay on — treatment.

Foundayo was approved under the FDA's National Priority Voucher Program, making it the first new molecular entity to receive this designation — a reflection of the agency's recognition that obesity treatment access remains a critical public health need.